News

Study published: Neurofeedback improves impulsive and aggressive behavior in psychopathic offenders

Neurofeedback enables psychopathic individuals to learn to self-regulate the activity of particular fronto-central brain areas involved in emotional evaluation and behavioral control.


30 March 2015

Ilmenau, Germany

This is the result of a first study conducted by researchers of the University of Tübingen, Germany, investigating the effects of Neurofeedback training on disinhibition, aggression, and antisocial behavior in severe criminal psychopaths.

The researches recruited 14 male psychopathic offenders serving long term sentences in forensic psychiatric institutions, who underwent 25 sessions of training of the slow cortical potentials. The participants of the study showed improved behavioral control and behavioral regulation as well as improved inhibition of impulsive and aggressive behavior. Further studies with larger samples and more adequate control conditions are recommended.

read publication

watch TV report (in German)

case study - Neurofeedback to control impulsivity in forensic patient

FDA acknowledges IEEE standard for neurofeedback devices

The Food and Drug Association (FDA) of the USA lists under new entries of recognized standards: IEEE Std 2010-2012 Practice for Neurofeedback Systems


1 February 2015

Ilmenau, Germany

Read FDA announcement (standard 17-13, IEEE Recommended Practice for Neurofeedback Systems, IEEE Std 2010-2012)

This industrial standard was issued in May 2012 by IEEE (Institute of Electrical and Electronics Engineers) as a collaboration of various manufacturers of neurofeedback devices, the International Society for Neurofeedback and Research (ISNR) and FDA. It enables manufacturers to describe basic components and functions of their neurofeedback systems. On the other hand it allows the users to compare the systems of different manufacturers. Our company had contributed to setting up this standard by providing our input of then over 10 years of experience in the development of neurofeedback devices.

Neurofeedback und NIRS for ADHD

In the past we mainly reported about training of the slow cortical potentials for ADHD. The Tübingen University shows in a video (German) a new approach which they are investigating in adult ADHD patients.


23 January 2015

University of Tübingen, Germany

Here they combine the THERA PRAX® neurofeedback system with near-infrared spectroscopy (NIRS).

In the NIRS neurofeedback oxygenated hemoglobin in the prefrontal cortex is measured and fed back. The patient is required to increase or decrease hemodynamic activity in the investigated cortex. The researches hope that this method increases the attention.

Pictures: Oliver Koll, Thanh Mai - CampusTV

watch video (German)

Neurofeedback training causes sustained reduction of epileptic seizures

A follow-up study of Tübingen University, Germany, shows that the training of the slow cortical potentials can sustainably improve symptoms of intractable epilepsy.


21 January 2015

University of Tübingen, Germany

Even more than 10 years after completion of a controlled clinical trial on SCP training in intractable epilepsie, those participants, who had taken part in the follow-up evaluation, were still able to control their SCPs during the feedback condition. Even more, there was a significant decrease in seizure frequency 10 years after the end of the neurofeedback training.

Besides the very small sample size in the follow-up evaluation, the scientists conclude that SCP training may be considered as a treatment for patients with intractable epilepsie and as an adjunct to conventional therapy.

Read study in PubMed

Safety of medicines used for ADHD in children

A metaanalysis of several studies on the long-term safety of drugs for ADHD with a total of over 2,200 children and adolescents reveals, that side effects are not rare.


10 January 2015

Ilmenau, Germany

Between 58 and 78% of all participants reported Adverse Events (AEs), most commonly decreased appetite, insomnia, headache and abdominal pain. Up to one quarter of the patients discontinued due to AEs.

Abstract